We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Read MoreHide Full Article
Key Takeaways
Sanofi gained FDA fast track designation for its gene therapy SAR402663 in wet AMD.
The tag allows rolling review, expediting SAR402663's regulatory process.
SAR402663 targets VEGF to reduce abnormal eye vessel growth and treatment burden.
Sanofi (SNY - Free Report) announced that the FDA granted fast track designation to its investigational gene therapy, SAR402663, for the treatment of neovascular (or wet) age-related macular degeneration (AMD).
How Does the Fast Track Tag Benefit SNY’s Drug Development?
Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, fill an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’
A candidate with the fast track designation is also eligible for rolling review. This will allow Sanofi to submit completed sections of its regulatory filing for SAR402663 to the FDA as they become available, rather than waiting for the entire application to be finalized. This can potentially expedite the evaluation process, as the FDA typically does not begin reviewing a submission until all sections of the application have been filed.
SNY’s Stock Performance
Shares of Sanofi have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
More on Sanofi’s SAR402663
An investigational one-time intravitreal gene therapy, SAR402663, is designed to inhibit vascular endothelial growth factor (VEGF) — a key driver of abnormal blood vessel growth in the eye. By targeting this pathway, the therapy aims to address the underlying disease pathology while reducing treatment burden by eliminating the need for frequent intravitreal injections.
Sanofi is currently evaluating SAR402663 in a phase I/II study for neovascular/wet AMD, a severe form of macular degeneration caused by growth of abnormal blood vessels beneath the retina. The condition, which can lead to vision loss and, in advanced stages, blindness, affects more than a million people in the United States.
Rival Gene Therapy Programs for Wet AMD
A key competitor to Sanofi’s SAR402663 is ABBV-RGX-314, a one-shot gene therapy being developed by AbbVie (ABBV - Free Report) in partnership with Regenxbio (RGNX - Free Report) . Also designed to target VEGF, this ABBV/RGNX candidate is being evaluated in pivotal studies for wet AMD, with data expected next year. AbbVie and Regenxbio are planning to start a late-stage program on ABBV-RGX-314 in patients with diabetic retinopathy (DR).
Another close competitor to the Sanofi therapy is 4D Molecular Therapeutics’ (FDMT - Free Report) lead pipeline candidate, 4D-150. Like SAR402663 and ABBV-RGX-314, 4D Molecular’s gene therapy candidate is also designed to target VEGF and is currently being evaluated in two late-stage studies for wet AMD. Data from these two studies are expected in the second half of 2027. FDMT also intends to start late-stage studies on 4D-150 in diabetic macular edema (DME).
Image: Bigstock
SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag
Key Takeaways
Sanofi (SNY - Free Report) announced that the FDA granted fast track designation to its investigational gene therapy, SAR402663, for the treatment of neovascular (or wet) age-related macular degeneration (AMD).
How Does the Fast Track Tag Benefit SNY’s Drug Development?
Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, fill an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earlier.’
A candidate with the fast track designation is also eligible for rolling review. This will allow Sanofi to submit completed sections of its regulatory filing for SAR402663 to the FDA as they become available, rather than waiting for the entire application to be finalized. This can potentially expedite the evaluation process, as the FDA typically does not begin reviewing a submission until all sections of the application have been filed.
SNY’s Stock Performance
Shares of Sanofi have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
More on Sanofi’s SAR402663
An investigational one-time intravitreal gene therapy, SAR402663, is designed to inhibit vascular endothelial growth factor (VEGF) — a key driver of abnormal blood vessel growth in the eye. By targeting this pathway, the therapy aims to address the underlying disease pathology while reducing treatment burden by eliminating the need for frequent intravitreal injections.
Sanofi is currently evaluating SAR402663 in a phase I/II study for neovascular/wet AMD, a severe form of macular degeneration caused by growth of abnormal blood vessels beneath the retina. The condition, which can lead to vision loss and, in advanced stages, blindness, affects more than a million people in the United States.
Rival Gene Therapy Programs for Wet AMD
A key competitor to Sanofi’s SAR402663 is ABBV-RGX-314, a one-shot gene therapy being developed by AbbVie (ABBV - Free Report) in partnership with Regenxbio (RGNX - Free Report) . Also designed to target VEGF, this ABBV/RGNX candidate is being evaluated in pivotal studies for wet AMD, with data expected next year. AbbVie and Regenxbio are planning to start a late-stage program on ABBV-RGX-314 in patients with diabetic retinopathy (DR).
Another close competitor to the Sanofi therapy is 4D Molecular Therapeutics’ (FDMT - Free Report) lead pipeline candidate, 4D-150. Like SAR402663 and ABBV-RGX-314, 4D Molecular’s gene therapy candidate is also designed to target VEGF and is currently being evaluated in two late-stage studies for wet AMD. Data from these two studies are expected in the second half of 2027. FDMT also intends to start late-stage studies on 4D-150 in diabetic macular edema (DME).
Sanofi Price
Sanofi price | Sanofi Quote
SNY’s Zacks Rank
Sanofi currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.